HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial

Creative Commons License

Files in This Item:
Cho_et_al-2019-Diabetes,_Obesity_and_Metabolism.pdf483.24 kBPDFView/Open
dom13557-sup-0001-appendixs1.docx Supporting Information: Appendix S114.44 kBMicrosoft Word XMLView/Open
dom13557-sup-0002-appendixs2.docxSupporting Information: Appendix S214.03 kBMicrosoft Word XMLView/Open
dom13557-sup-0003-appendixs3-2.pptxSupporting Information: Supplemental Figures62.42 kBMicrosoft Powerpoint XMLView/Open
dom13557-sup-0003-appendixs3.docxSupporting Information: Supplemental Figure Legends11.92 kBMicrosoft Word XMLView/Open
dom13557-sup-0004-tables1.docxSupporting Information: Table S113.94 kBMicrosoft Word XMLView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/72905

Title: Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial
Authors: Cho, Kyu Yong Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Omori, Kazuno Browse this author
Takase, Takahiro Browse this author
Miya, Aika Browse this author
Manda, Naoki Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: body weight control
cardiovascular disease
randomized trial
SGLT2 inhibitor
thiazolidinediones
type 2 diabetes
Issue Date: Mar-2019
Publisher: Wiley
Journal Title: Diabetes, Obesity and Metabolism
Volume: 21
Issue: 3
Start Page: 710
End Page: 714
Publisher DOI: 10.1111/dom.13557
Abstract: The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy-one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non-inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT-proBNP, P < 0.01; ACR, P = 0.02), and the change in NT-proBNP correlated negatively with baseline NT-proBNP level (ρ = -0.68, P < 0.01) and log-converted ACR (ρ = -0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events.
Rights: http://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/72905
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University